# A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children

> **NCT02207413** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1886 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Influsplit Tetra™ vaccine produced by investigational process (IP)
- **BIOLOGICAL:** Influsplit Tetra™ vaccine produced by licensed process (LP)

## Key facts

- **NCT ID:** NCT02207413
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-18
- **Primary completion:** 2015-04-18
- **Final completion:** 2015-04-18
- **Target enrollment:** 1886 (ACTUAL)
- **Last updated:** 2018-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02207413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02207413, "A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02207413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*